TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation
TRANSCENTA-B (06628.HK) announced positive interim data from its partner Inhibrx Biosciences' Phase 1/2 study of ozekibart in colorectal cancer. Inhibrx also submitted a Biologics License Application (BLA) for ozekibart in conventional chondrosarcoma to the FDA. Transcenta holds exclusive rights for ozekibart in Greater China and is evaluating its plans in the region based on these developments.
Liquidity Mapping Around (INBX) Price Events
This article provides a liquidity mapping analysis for Inhibrx Biosciences Inc Com (NASDAQ: INBX), indicating weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights a significant 95.7:1 risk-reward setup for a potential 27.3% gain.
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study
Inhibrx Biosciences announced positive results from a Phase 2 study where its INBRX-106 in combination with KEYTRUDA showed superior overall response rates compared to KEYTRUDA alone in patients with advanced solid tumors. The combination therapy achieved a higher overall response rate, particularly in PD-L1 positive patients. These findings suggest a promising new treatment approach for specific cancer types, especially those expressing PD-L1.
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230
LifeSci Capital analyst Oliver McCammon has reiterated a "Buy" rating for Inhibrx Biosciences (INBX.US) and maintained a target price of $230. According to TipRanks data, the analyst has a 64.9% success rate and an average return of 88.0% over the past year. This report highlights the analyst's continued positive outlook on the company's stock.
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter
Viking Global has reported its beneficial ownership in Inhibrx (INBX) through an amended SCHEDULE 13G/A filing, indicating holdings of 1,461,633 shares, which represent 9.99% of the company's outstanding common stock. The amendment also noted the removal of David C. Ott as a reporting person due to his retirement, effective March 31, 2026. The filing details how ownership is allocated among various Viking Global entities and explains a "Blocker" mechanism for warrants that prevents ownership from exceeding 9.99% (with a potential increase to 19.99% after notice).
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amended Schedule 13G/A, reporting a shared beneficial ownership of 9.99% in INHIBRx Biosciences (INBX). This stake, totaling 1,461,105 shares, is based on 14,607,286 outstanding shares as of April 7, 2026, and includes pre-funded warrants subject to a beneficial ownership limitation. The filing details that the Master Fund directly holds common stock and pre-funded warrants, with Perceptive Advisors and Joseph Edelman identified as beneficial owners by attribution.
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing
This article provides a SWOT analysis of Inhibrx Biosciences Inc (INBX) based on its latest 10-Q filing. It highlights the company's strong pipeline of therapeutic candidates and focus on R&D as strengths, while pointing out significant financial weaknesses, including ongoing operating losses and low profitability. Opportunities exist in clinical trial advancements and strategic partnerships, though threats include intense competition and reliance on external funding.
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. reported its financial results for the first quarter of 2026, highlighting a net loss of $33.4 million, an improvement from the $43.3 million loss in Q1 2025. The company also announced key clinical trial updates for INBRX-106 and ozekibart (INBRX-109), including planned data announcements and regulatory interactions with the FDA for potential accelerated pathways. Cash and cash equivalents increased to $161.7 million due to additional loan proceeds.
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt
Inhibrx Biosciences reported a narrower net loss of $33.4 million in Q1 2026, down from $43.3 million in Q1 2025, primarily due to reduced R&D expenses. The company's cash and cash equivalents increased to $161.7 million, bolstered by an additional $75.0 million in loan proceeds, which also raised long-term debt to $175.0 million and resulted in a stockholders' deficit. Inhibrx advanced its clinical pipeline with updated interim data for INBRX-106 and ozekibart, and submitted a Biologics License Application for ozekibart in conventional chondrosarcoma.
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings
Inhibrx Inc (INBX), a clinical-stage biotechnology firm, is a top holding in the Virtus Biotech Clinical Trials ETF (BBC), signaling its importance in clinical innovation for US investors. The company specializes in developing precision protein therapeutics for oncology, immunology, and rare diseases, with key assets like INBRX-109 in Phase 1 trials. Its presence in the Nasdaq-listed ETF offers US investors direct access to its growth potential tied to trial outcomes and partnerships.
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences (NASDAQ: INBX) announced positive interim results from the Phase 2 portion of its HexAgon study for INBRX-106 in combination with pembrolizumab for Head and Neck Squamous Cell Carcinoma. The study achieved a 44.0% confirmed Objective Response Rate, with most responding patients showing significant tumor reductions and three achieving complete radiographic responses. Stifel subsequently raised its price target on INBX to $300 from $150, maintaining a 'Buy' rating.
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Inhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions compared to pembrolizumab alone. The study demonstrated robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 and explore broader indications for OX40 agonism.
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Inhibrx Biosciences reported positive interim results from its Phase 2 HexAgon study for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions. This combination demonstrated a 22.6% absolute increase in confirmed responses compared to pembrolizumab alone, along with robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 in Q3 2026 and explore INBRX-106 in broader indications like non-small cell lung cancer.
Inhibrx Biosciences reports positive Ph2 trial data, stock gains
Inhibrx Biosciences' shares rose in premarket trading after the company announced positive interim results from the Phase 2 portion of its HexAgon study. The trial, evaluating INBRX-106 in combination with pembrolizumab for Head and Neck Squamous Cell Carcinoma, showed a significantly higher Objective Response Rate compared to pembrolizumab alone. The combination also demonstrated a manageable safety profile, with progression-free survival data expected in Q4 2026.
Inhibrx Biosciences (INBX) Stock Jumps 17% on Positive Cancer Trial Results
Inhibrx Biosciences (INBX) saw its stock jump 17% following positive preliminary Phase 2 HexAgon study results for its head-and-neck cancer drug, INBRX-106. The drug, when combined with pembrolizumab, achieved a 44% objective response rate compared to 21.4% for pembrolizumab alone, along with significant T-cell proliferation and a manageable safety profile. Phase 3 of the trial is expected to begin in Q3 2026, with progression-free survival data anticipated in Q4 2026.
Should Positive INBRX-106 Phase 2 Combo Data in Head and Neck Cancer Require Action From Inhibrx Biosciences (INBX) Investors?
Inhibrx Biosciences reported positive interim Phase 2 data for INBRX-106 in combination with pembrolizumab for head and neck cancer, showing improved response rates and T-cell activation. While these results support plans for a Phase 3 trial and broader exploration, the company faces ongoing financial losses and high valuation concerns. Investors must weigh the strengthening clinical pipeline against risks related to funding, execution, and the interim nature of the data.
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
Inhibrx Biosciences (INBX) announced positive interim Phase 2 results for its HexAgon trial, evaluating INBRX-106 plus pembrolizumab for head and neck squamous cell carcinoma. The combination arm showed a 44% objective response rate with three complete responses, significantly higher than the control arm. The company plans to advance to Phase 3 in Q3 2026 and expand INBRX-106 into other immuno-oncology indications.
INBRX-106 boosts response in HNSCC for Inhibrx (Nasdaq: INBX) with Phase 2 results
Inhibrx (Nasdaq: INBX) reported positive interim Phase 2 results for its drug candidate INBRX-106 in combination with pembrolizumab for first-line head and neck squamous cell carcinoma (HNSCC). The combination therapy achieved a 44.0% objective response rate, significantly higher than pembrolizumab alone (21.4%), and demonstrated increased T-cell activation. The company plans to advance to Phase 3 in Q3 2026 and explore expansion into broader indications, projecting a potential market of $50 billion.
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230
LifeSci Capital has reiterated its Buy rating on Inhibrx Biosciences (INBX.US) and increased its price target to $230. This update suggests a strong positive outlook from the analytical firm regarding the company's future stock performance.
A Look At Inhibrx Biosciences (INBX) Valuation As Investors Await Phase 2 HexAgon Webcast Results
Inhibrx Biosciences (INBX) has seen significant share price appreciation (100% in 30 days, 10x in a year) as investors anticipate Phase 2 HexAgon data, despite a recent 12% decline. The company is trading at a high price-to-book multiple of 227.6x, indicating that its valuation is heavily based on future pipeline potential rather than current assets, suggesting it is overvalued compared to industry peers. Investors are advised to consider the risks, such as potential clinical trial setbacks, and to review the underlying data.
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data
Shares of Inhibrx Biosciences (INBX) climbed 17% after announcing encouraging interim Phase 2 clinical trial data for INBRX-106 in head-and-neck cancer treatment. The combination therapy with pembrolizumab achieved a 44% objective response rate, significantly outperforming pembrolizumab monotherapy's 21.4%. The company plans to initiate Phase 3 enrollment in Q3 2026, with progression-free survival outcomes expected by Q4 2026.
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know.
Inhibrx Biosciences' stock saw a significant surge after the company released positive preliminary results from its trial of a new treatment for head-and-neck cancer. The biotech stock has already experienced a remarkable increase of over 1,000% in the past year. This development highlights potential advancements in cancer treatment and reinforces investor confidence in Inhibrx.
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx announced positive interim results from its Phase 2 HexAgon study for INBRX-106 in combination with pembrolizumab for first-line Head and Neck Squamous Cell Carcinoma. The combination arm achieved a 44.0% confirmed Objective Response Rate (cORR), a 22.6% absolute increase over pembrolizumab monotherapy, alongside superior tumor reductions and robust systemic T-cell expansion. These results suggest INBRX-106 could significantly enhance immunotherapy efficacy, with plans to advance to Phase 3 and explore broader indications.
A Look At Inhibrx Biosciences (INBX) Valuation As Investors Await Phase 2 HexAgon Webcast Results
Inhibrx Biosciences (INBX) is garnering attention following a significant share price increase and an upcoming webcast for its Phase 2 HexAgon data. While the stock has seen substantial gains, trading at 227.6x price-to-book against a peer average of 2.8x, it appears "OVERVALUED" according to a Simply Wall St valuation analysis. Investors are cautioned about clinical trial risks and the company's reliance on limited revenue and ongoing losses, despite a high analyst target price.
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx Biosciences will host a live webcast presentation on Monday, May 11, 2026, to provide interim results from the Phase 2 portion of the HexAgon study for INBRX-106. This study evaluates INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab versus pembrolizumab monotherapy in first-line patients with metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). Investors can join the webcast via web or phone.
Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data
Inhibrx Biosciences (NASDAQ:INBX) shares were trading higher in premarket ahead of its Phase 2 head and neck cancer drug data. The company is expected to release data from the study of INBRX-109 later in the day, with investors anticipating positive results.
Jon Najarian: Inhibrx Biosciences gains after hours on phase 2 trial update
Inhibrx Biosciences saw a 7% increase in after-hours trading following an announcement that it will release interim results on May 11 from its phase 2 trial of INBRX-106. The trial is for first-line head and neck squamous cell carcinoma, and co-founder of Market Rebellion, Jon Najarian, noted growing optimism regarding the anticipated results.
Inhibrx to share interim Phase 2 head and neck cancer data Monday
Inhibrx (NASDAQ: INBX) will host a webcast on May 11, 2026, to provide interim clinical results from its randomized Phase 2 HexAgon study. The study evaluates INBRX-106 plus pembrolizumab against pembrolizumab alone in first-line, PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). This update has already led to an 8.09% increase in INBX stock, reflecting positive market reaction.
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx Biosciences, Inc. announced it will host a live webcast on Monday, May 11, 2026, to present interim results from the HexAgon study of INBRX-106. This study evaluates INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab for first-line treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). The presentation will provide a clinical update on the safety and efficacy of this treatment in patients with previously untreated, PD-L1 positive metastatic or unresectable recurrent HNSCC.
Why (INBX) Price Action Is Critical for Tactical Trading
This article from Stock Traders Daily analyzes Inhibrx Biosciences Inc (INBX) stock, highlighting strong sentiment across all horizons despite elevated downside risk due to a lack of long-term support signals. It outlines institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for tactical trading.
A Look At Inhibrx Biosciences (INBX) Valuation After New Ozekibart Data And BLA Submission
Inhibrx Biosciences (INBX) is experiencing significant market attention due to updated interim data for ozekibart in colorectal cancer and its Biologics License Application submission for conventional chondrosarcoma. Despite a 92.19% increase in share price over 30 days and a large total shareholder return over the past year, the company's valuation is considered expensive with a P/B ratio of 236.1x against limited current revenue and ongoing losses. Investors are advised to review the valuation given the high price-to-book ratio and the company's unprofitability.
Inhibrx Biosciences urges sustained research to accelerate oncology breakthroughs
Inhibrx Biosciences emphasizes the critical need for sustained scientific research to drive breakthroughs in oncology, particularly during National Cancer Research Month. The company advocates for continuous investment in understanding cancer and developing innovative treatments. Inhibrx has a history of supporting research into rare sarcoma cancers and patient advocacy efforts, aligning with its current focus on advancing oncology research.
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today & Analysis
This article provides a stock analysis for Inhibrx Biosciences, Inc. (INBX), covering its current stock price, fundamental financials, and corporate information. It also offers a guide on how to buy INBX stock through the Gotrade app, explains its dividend policy, and gives advice on how to evaluate if the stock is expensive or cheap.
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Biosciences Inc. (INBX) has reported its third-quarter 2025 financial results. This report was delivered via Quantisnow, a real-time market data and news platform. The article also provides recent analyst ratings and related SEC filings and press releases concerning the company.
How Investors May Respond To Inhibrx Biosciences (INBX) Ozekibart Colorectal Data And FDA Filing Moves
Inhibrx Biosciences (INBX) recently released updated interim Phase 1/2 data for ozekibart in metastatic colorectal cancer, showing promise, alongside a Biologics License Application filing for ozekibart in conventional chondrosarcoma. These developments reinforce ozekibart as the primary value driver for Inhibrx, although the company's reliance on a single asset and ongoing losses present investment risks. Investors will be closely watching FDA feedback, potential accelerated pathways, and the initiation of a first-line CRC registrational trial as key milestones.
Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) stock from a "sell" to a "hold" rating, aligning with an overall "Hold" consensus and a $150.00 price target from analysts. The company recently reported a quarterly EPS of ($2.11), missing estimates, and institutional investors like Perceptive Advisors and Morgan Stanley have increased their stakes. Inhibrx Biosciences is a clinical-stage biotech company focusing on next-generation protein therapeutics, with 82.46% of its stock owned by institutional investors.
INBX Price Today: Inhibrx Biosciences, Inc. Stock Price, Quote & Chart | MEXC
This article provides details on Inhibrx Biosciences, Inc. (INBX) stock, including its current trading price of $128.84, a -0.27% daily change, and significant annual growth of +960.39%. It summarizes key market data such as market cap, 52-week high/low, and EPS, and includes a Q&A section for investors. The article also outlines how to buy INBX stock on MEXC.
Inhibrx Biosciences president granted 50K options | INBX Insider Trading
Inhibrx Biosciences President David Matly was granted 50,000 stock options with an exercise price of $129.06 per share, expiring on April 24, 2036. The options will vest over time, with 25% exercisable on April 24, 2027, and the remainder vesting monthly over the subsequent 36 months, conditional on his continuous service to the company. After this grant, Matly directly holds 50,000 stock options.
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200
LifeSci Capital has reiterated its Buy rating on Inhibrx Biosciences (INBX.US) and maintained a target price of $200. This continued endorsement suggests the firm's confidence in the company's future performance.
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
Inhibrx Biosciences reported positive Phase I/II data for ozekibart in combination with FOLFIRI for heavily pretreated advanced colorectal cancer, achieving a 20% objective response rate and 5.5 months median progression-free survival. The company plans to pursue a first-line registrational study, second and third-line cohorts, and potentially accelerated regulatory pathways, emphasizing the drug's manageable safety profile and broader solid tumor potential.
Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital
Lifesci Capital upgraded Inhibrx Biosciences (NASDAQ:INBX) to a "strong-buy" rating, though the overall analyst consensus remains "Hold" with an average price target of $150.00. The clinical-stage biotech firm reported a quarterly EPS miss of ($2.11) and analysts forecast an EPS of -11.15 for the current fiscal year. Inhibrx specializes in multispecific protein therapeutics, with its lead candidate INBRX-109 focused on tissue repair and regeneration.
Inhibrx Biosciences commits to sustainability with new Earth Day measures
Inhibrx Biosciences unveiled new sustainability initiatives for Earth Day, focusing on strengthening workplace culture through intentional connections and creative spaces. These efforts align environmental responsibility with organizational innovation, reflecting a broader corporate ethos that also includes recent collaboration with the Sarcoma Alliance and expanded research into rare sarcoma cancers. The company's commitment to sustainability is presented as an integral part of its corporate identity.
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4% - Should You Buy?
Inhibrx Biosciences (NASDAQ:INBX) shares increased by 9.4% to $125.86 on Thursday, though trading volume was below average. Analysts offer mixed opinions with a consensus "Hold" rating and a $150 price target, with some initiating "Buy" coverage while others have downgraded or maintained cautious views. The clinical-stage biotech has a market cap of approximately $1.86 billion and negative earnings, with its lead program being INBRX-109.
INBX stock hit record highs: Cancer therapies reportedly draw big pharma interest
INBX stock has surged to record highs based on reports that its cancer therapies are attracting significant interest from major pharmaceutical companies. This news suggests potential acquisition or partnership opportunities for INBX, capitalizing on its innovative treatments. The increased attention from big pharma underscores the perceived value and future prospects of INBX's oncology pipeline.
Why Inhibrx Biosciences (INBX) Is Up 44.3% After Ozekibart Colorectal Cancer Efficacy Update And What's Next
Inhibrx Biosciences (INBX) saw a 44.3% stock increase following promising interim Phase 1/2 data for ozekibart in colorectal cancer and the advancement of a Biologics License Application for the drug in conventional chondrosarcoma. The drug demonstrates potential as a first-in-class DR5 agonist across multiple difficult-to-treat solid tumors. While the company still faces challenges like minimal revenue and significant losses, these updates have sharpened its near-term catalyst map and reinforced its investment narrative.
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Major drugmakers are reportedly interested in Inhibrx Biosciences' experimental cancer therapy, INBRX-106, which could be valued at over $8 billion, potentially alongside another early-stage oncology asset pushing the combined value past $9 billion. This interest is driven by INBRX-106's potential as a standalone therapy and in combination with Merck's Keytruda, with clinical trial data expected in 2026. The strategic timing aligns with Keytruda's patent expiry, attracting several pharmaceutical companies as potential suitors.
[ARS] Inhibrx Biosciences, Inc. SEC Filing
This article announces an SEC filing (Form ARS) by Inhibrx Biosciences, Inc. (INBX) on April 23, 2026, at 04:09 PM. The filing's sentiment is neutral, and its impact is low. The article provides details about the filing, links to the PDF document on SEC EDGAR, and includes general information about Inhibrx Biosciences, such as market cap, industry, and recent news and SEC filings.
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences (INBX) shares surged 36.9% following positive interim data from a Phase I/II study of ozekibart in colorectal cancer, showing a 20% objective response rate in heavily pretreated patients. The company also filed a Biologics License Application (BLA) for ozekibart in conventional chondrosarcoma and plans to engage with the FDA for a first-line CRC registrational study and potential accelerated pathways for Ewing sarcoma. Inhibrx is also evaluating another clinical candidate, INBRX-106, in combination with Keytruda for lung and head and neck cancers.
INBX Stock Jumps As Ozekibart Data Draws $150 Target
Inhibrx Biosciences Inc. (INBX) stock jumped by 36.88% due to positive interim Phase 1/2 data for its drug ozekibart in metastatic colorectal cancer, showing a 20% objective response rate and manageable safety. The company plans an FDA meeting for a first-line trial and has a Biologics License Application for ozekibart in conventional chondrosarcoma. Stifel initiated coverage with a Buy rating and a $150 price target, highlighting the drug's potential.
Inhibrx Biosciences stock surges on takeover interest report
Inhibrx Biosciences (NASDAQ:INBX) shares surged over 20% following reports that the company has attracted acquisition interest from major drugmakers, including Merck & Co, Germany’s Merck KGaA, and Japan’s Ono Pharmaceutical. The interest primarily focuses on its experimental cancer treatment, INBRX-106, which could be valued at over $8 billion depending on clinical trial results. While talks are in early stages, the biotech is also exploring a joint spin-off of INBRX-106 and another experimental cancer treatment, potentially valued at more than $9 billion successfully.
